Individualised GH therapy in children by Bioactive IGF-I
Background
Treatment with GH includes IGF-I monitoring, and the EMAS labelling suggest to keep total IGF-I concentrations below +2 SD during GH therapy. This is a logical and physiogical rationale in children with GH deficiency, but rarely possible in children treated with pharmacological GH doses for non-GHD conditions. However, we recently suggested that a novel assay to measure bioactive IGF-I was superior to the conventional total IGF-I quantification
Aims and Study Design
To validate bioactive IGF-I as a new tool in monitoring of GH therapy in children. Serum samples from children in GH therapy will in addition to rutine measurement of immunoreactive IGF-I for monitoring also be analysed by a newly developed multiplex mass spectrometry method, which co-measures IGF-II and several IGF-binding proteins as well as by the novel assay for bioactive IGF-I.
The Research Team
This study is a two-center study between EDMaRC / Dept. of Growth and Reproduction, Rigshospitalet and Pediatric Department, Odense University Hospital.
Funding
The study received a grant from the OUH-RH grant committee.
Key EDMaRC researcher in the project:
Anders Juul
MDSc, Professor
Principal Investigator
MDSc, Professor
Principal Investigator